Indoco Remedies' new solid dosages facility at Baddi gets UK-MHRA nod

Indoco Remedies' new Baddi facility is spread over an area of 18000 sqm, with a manufacturing capacity of 4.3 billion tablets and 50 million capsules p.a.

Mumbai: Indoco Remedies Limited recently announced that it has received approval from the UKMHRA (Medicines and Healthcare Products Regulatory Agency) for its new solid dosages manufacturing facility in Baddi, Himachal Pradesh (Baddi III unit).

The inspection was held from 16th to 18th October 2018. The facility is spread over an area of 18000 sqm, with a manufacturing capacity of 4.3 billion tablets and 50 million capsules p.a.

Read Also: Indoco Remedies: USFDA retains OAI status for Goa plant

Commenting on the approval, Managing Director, Indoco Remedies Limited, Ms Aditi Panandikar said, "This is the first Regulatory inspection for the plant, which was acquired in 2016."

"The outcome of this inspection is positive and is a testimony that Indoco maintains global quality standards and follows strict GMP guidelines. The facility will cater mainly to the European markets," Panandikar added.

Headquartered in Mumbai, Indoco Remedies is a fully integrated, research-oriented pharma company and has nine manufacturing facilities. It has a presence across 55 countries.

Read Also: USFDA inspected Goa facility, no observations issued: Indoco Remedies